Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease: Committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.